Table 3 Characteristics of patients who developed dizziness or somnolence
Duration of pregabalin therapy | N | Developed somnolence or dizziness |
 ≤2 weeks | 21 (10.8 %) | 8 (38.1 %) |
 >2 weeks–≤1 month | 30 (15.4 %) | 7 (23.3 %) |
 >1 month–≤2 months | 36 (18.5 %) | 11 (30.6 %) |
 >2 months | 108 (55.4 %) | 37 (34.3 %) |
 Median (day, range) | 78 (1–740) |  |
Dosage | N | Developed somnolence or dizziness |
 Within the defined initial dosage range | 166 (85.1 %) | 52 (31.3 %) |
 Over the defined initial dosage range | 29 (14.9 %) | 11 (37.9 %) |
Concomitant drugs with pregabalin | N | Developed somnolence or dizziness |
 Oral hypoglycemic drugs | 28 (14.4 %) | 6 (21.4 %) |
 Antihypertensive drugs | 55 (28.2 %) | 15 (27.2 %) |
 NSAID | 64 (32.8 %) | 15 (23.4 %) |
 Opioid pain relievers | 54 (27.7 %) | 25 (46.3 %) |
 CNS- depressants | 31 (15.9 %) | 9 (29.0 %) |